Rani Therapeutics Holdings (RANI) EBIT (2020 - 2026)

Rani Therapeutics Holdings has reported EBIT for 7 years, with the latest figure at -$8.8 million in Q2 2026.

• On a quarterly basis, EBIT rose 15.96% year-over-year to -$8.8 million in Q2 2026; TTM through Jun 2026 was -$33.0 million, a 33.11% increase from a year earlier, with the FY2025 full-year figure at -$38.3 million, up 28.14% from the prior year.
• EBIT was -$8.8 million for Q2 2026 at Rani Therapeutics Holdings, down from -$8.3 million in the prior quarter.
• The five-year high for EBIT was -$7.3 million in Q3 2025, with the low at -$18.3 million in Q2 2023.
• Average EBIT over 5 years is -$13.2 million, with a median of -$13.6 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: EBIT plunged 201.39% in 2022, then jumped 42.94% in 2025.
• Over 5 years, EBIT stood at -$17.5 million in 2022, then advanced by 23.16% to -$13.4 million in 2023, then dropped by 11.34% to -$15.0 million in 2024, then soared by 42.94% to -$8.5 million in 2025, then declined by 3.43% to -$8.8 million in 2026.
• The last three EBIT figures came in at -$8.8 million (Q2 2026), -$8.3 million (Q1 2026), and -$8.5 million (Q4 2025), per Business Quant data.